DEF: Cartesian Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Cartesian Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 13, 2025, to vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.

Summary

• Cartesian Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders on June 13, 2025, as a virtual meeting.
• Stockholders will vote on three proposals: electing three Class III Directors, approving executive compensation on an advisory basis, and ratifying the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR all three proposals.
• The record date for determining stockholders eligible to vote is April 14, 2025.
• As of the record date, there were 25,937,101 shares of Common Stock outstanding and entitled to vote.
• The proxy statement and the company's Annual Report on Form 10-K for the year ended December 31, 2024, were released on or about April 28, 2025.
• The meeting will include a live webcast where stockholders can submit questions and vote electronically.
• The Board is divided into three classes with staggered three-year terms, with Class III directors being elected at this meeting to serve until the 2028 Annual Meeting.
• The company has adopted Corporate Governance Guidelines, a Code of Business Conduct and Ethics, and charters for its Board committees.
• The Board is committed to diversity and inclusion, considering a wide variety of factors in the director nomination process.
• The company has an Insider Trading Policy that prohibits hedging and pledging of company securities.
• The Audit Committee has reviewed the company's audited financial statements for the fiscal year ended December 31, 2024, and recommended their inclusion in the Annual Report on Form 10-K.
• Ernst & Young LLP's fees for audit services in 2024 were $750,000, audit-related fees were $173,000, and tax fees were $66,195.
• The Compensation Committee uses competitive compensation data from peer companies to inform decisions about executive compensation.
• The company has a compensation recovery (clawback) policy allowing recovery of incentive compensation in the event of a financial restatement due to fraud or misconduct.
• The company has employment agreements with Named Executive Officers that provide for post-employment compensation in certain circumstances.
• The company prohibits employees, including officers and directors, from (i) engaging in hedging transactions involving the Company’s securities and (ii) pledging the Company’s securities as collateral for loans of any type without the prior approval of the Chief Executive Officer, Chief Financial Officer, or General Counsel.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting factual information about the upcoming annual meeting and proposals. The Board's recommendations suggest a positive outlook, but the document primarily serves an informational purpose.

Positives

• The company is providing stockholders with a virtual meeting option for increased accessibility.
• The Board is recommending a vote FOR all proposals, indicating confidence in the company's direction.
• The company has a clawback policy in place, promoting accountability.
• The company has an Insider Trading Policy that prohibits hedging and pledging of company securities.
• The Audit Committee has reviewed the company's audited financial statements and recommended their inclusion in the Annual Report on Form 10-K.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or control of the company.
• Directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the outstanding voting stock.
• The proxy holders named on the company's proxy card will vote your shares in accordance with their best judgment if any other matter properly comes before the stockholders for a vote at the Annual Meeting.

Future Outlook

The document does not contain a specific future outlook section, but it implies continued operations and development through the proposals for director elections and auditor ratification.

Management Comments

• Carsten Brunn, Ph.D., President and Chief Executive Officer, urges stockholders to promptly vote and submit their proxy.
• Carsten Brunn, Ph.D., thanks stockholders for their continued support and investment in Cartesian Therapeutics, Inc.

Industry Context

The document reflects standard corporate governance practices for a publicly traded biotechnology company, including annual meetings, proxy statements, and board oversight.

Comparison to Industry Standards

• The director compensation structure, including retainers and equity awards, appears consistent with industry practices for similarly sized biotechnology companies.
• The engagement of an independent compensation consultant (Compensia) is a common practice to ensure executive compensation is aligned with market rates and performance.
• The company's clawback policy and insider trading policy align with regulatory requirements and best practices for corporate governance.
• The virtual annual meeting format is increasingly common, especially for companies with geographically dispersed stockholders.

Stakeholder Impact

• Stockholders are directly impacted by the proposals being voted on, including the election of directors and the approval of executive compensation.
• Employees are indirectly impacted through the approval of executive compensation and the overall governance of the company.
• The company's independent auditor is directly impacted by the ratification vote.

Next Steps

• Stockholders are urged to vote on the proposals before the Annual Meeting.
• The company will hold the Annual Meeting on June 13, 2025.
• The Audit Committee will consider the outcome of the auditor ratification vote when appointing the independent auditors for the fiscal year ending December 31, 2026.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Election of Directors, Executive Compensation, Ernst & Young, Audit Committee, Corporate Governance, Common Stock, Cartesian Therapeutics